Possible Role of Osteoprotegerin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand as Markers of Plaque Instability in Coronary Artery Disease

Abstract

Osteoprotegerin (OPG) produced by cardiovascular system raising the possibility that alterations of OPG serum levels may be associated with coronary artery disease (CAD). Our aim is to assess the possible role of serum OPG and soluble tumor necrosis factor-related apoptosis-inducing ligand (s-TRAIL) in the pathology of CAD and their uses as markers of plaque stability. A total of 80 male participants were categorized into 3 groups: 28 patients with acute myocardial infarction (AMI), 32 established stable CAD, and 20 healthy controls were enrolled in this study. Acute myocardial infarction and CAD groups exhibited significantly higher OPG levels and lower s-TRAIL levels compared to the stable CAD and control participants. These results are aggravated as the number of affected coronary vessels increase in AMI and stable CAD groups. Conclusion: There is an association between raised serum OPG and reduced s-TRAIL in patients with CAD. Elevation of circulating OPG levels may represent a crucial compensatory mechanism to limit further vascular damage.

Keywords

osteoprotegerin tumor necrosis factor-related apoptosis-inducing ligand acute myocardial infarction coronary artery disease

Get full access to this article

View all access options for this article.

References

Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):115-126.

Glass CK , Witztum JL The road ahead. Atherosclerosis. 2001; 104(4):503-516.

Libby P. Inflammation in atherosclerosis. Nature. 2002 ;26: 420(6917):868-874.

Hansson GK , Libby P. , Schonbeck U. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91(4): 281-291.

Libby P. Molecular bases of the acute coronary syndromes. Circulation . 1995;91(11):2844-2850.

Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365-372.

Bucay N. , Sarosi I. , Dunstan CR Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Gene Dev. 1998;12(9):1260-1268.

Emery JG , McDonnell P. , Burke MB , et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL . J Biol Chem. 1998; 273(23):14363-14367.

Pritzker LB , Scatena M. , Giachelli CM The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Cell Biol. 2004;15(6):2834-2841.

10.

Sheridan JP , Marsters SA , Pitti RM , et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277(5327):818-821.

11.

Sprick MR , Weigand MA , Rieser E. , et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000; 12(6):599-609.

12.

Wang S. , El-Deiry WS TRAIL and apoptosis induction by TNFfamily death receptors. Oncogene. 2003;22(53):8628-8633.

13.

Jo M. , Kirn TH , Seol DW , et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000;6(5):564-567.

14.

Criteria committee of New York Heart Association. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. Boston, MA: Little, Brown and Company Inc; 1964:114.

15.

Yano K. , Tsuda E. , Washida N. , et al. Immunological characterization of circulating osteoprotegerin /osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14(4):518-527.

16.

Schoppet M. , Preissner KT , Hofbauer LC RANK ligand and Osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22(4): 549-553.

17.

Dhore CR , Cleutjens JP , Lutgens E. Differential expression of bone matrix regulatory proteins inhuman atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2003 ;21(12):1998-2003.

18.

Jono S. , Ikari Y. , Shioi A. Serum Osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002 ;106(10):1192-1194.

19.

Schoppet M. , Sattler AM , Schaefer JR , Herzum M. , Maisch B. Hofbauer LC Increased Osteoprotegerin serum levels in men with coronary artery disease. Clin Endocrinol Metab. 2003; 88(3):1024-1028.

20.

Kiechl S. , Schett G. , Wenning G. , et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004 ;109(18):2175-2180.

21.

Crisafulli A. , Micari A. , Altavilla D. , et al. Serum levels of Osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci. 2005;109(4):389-395.

22.

Wexler L. , Brundage F. , Crouse J. , et al. Coronary artery calcification: pathophysiology, epidemiology and clinical implications. Circulation. 1996 ;94(5):1175-1192.

23.

Leho S. , Niskanen L. , Suhonen M. , Ronnemaa T. , Laakso M. A neglected harbinger of cardiovascular complication in NIDDM. Arterioscler. Thromb Vasc Biol. 1996;16(8):978-983.

24.

Min H. , Morroni S. , Sarrosi I. Osteoprotegrin reverses osteoporsis by inhibiting osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis . J Exp Med. 2000;192(4):463-474.

25.

Collin-Osdoby P. , Rothe L. , Anderson E. , Nelson M. , Maloney W. , Osdoby P. Receptor activator of NF-κβ and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem . 2001;276(23):20659-20672.

26.

Libby P. , Ridker PM , Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-1143.

27.

Hofbauer LC , Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490-495.

28.

Paoletti R. , Gotto AM Jr , Hajjar DP Inflammation in atherosclerosis and implications for therapy. Circulation. 2004; 109(23 suppl 1):20-26.

29.

Labarrere CA , Zaloga GP C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med. 2004;117(7):499-507.

30.

Rhee EJ , Lee WY , Kim SY , et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci. 2005;108(3): 237-243.

31.

Browner WS , Lui LY , Cummings SR Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86(2):631-637.

32.

Sato K. , Niessner A. , Stephen LK , Frye RL , Weyand CM TRAIL expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. JEM. 2006;203(1):239-250.

33.

Hanasson GK , Holm J. , Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaques. Am J Pathol. 1989;135(1):169-175.

34.

Schoppet M. , Sattler AM , Schaefer JR , Hofbauer LC Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in atherosclerosis. Atherosclerosis . 2006;184(2): 446-447.

35.

Michowitz Y. , Goldstein E. , Roth A. , et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand in atherosclerosis. J Am Coll Cardiol. 2005;45(7):1018-1024.

36.

Secchiero P. , Corallini F. , Beltrami AP , et al. An imbalanced OPG/ TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis . 2009 Nov 10. [Epub ahead of print].